Professor, Pharmacology & Toxicology
My current research interests focus on:
1. Understanding and manipulating the Renin-Angiotensin System (RAS) relevant to hypertension and diabetes.
2. Use of MALDI- TOF-MS and SELDI-TOF-MS to develop and optimize miniaturized novel assays for quantitative evaluation of localized and circulating RAS.
3. Our recent work focused on the development of urinary Angiotensin Converting Enzyme (ACE2 ) and neprilysin (NEP) as biomarkers for early detection of Chronic Kidney Disease in diabetic patients.
Our laboratory uses radio telemetry, confocal microscopy, western blot and enzyme assay to investigate the effect of hyperglycemia on blood pressure, renal RAS and progression of CKD in murine model of diabetes and hypertension.
Previous research interests were focused on extraction, purification and characterization of insulin mimetic molecules from Plasmodium yoelii. These molecules are related to Glycosylphosphatiylinositos (GPIs) which could have a potential as new antidiabetic agents.
Research is funded by NHLBI, American Heart Association, WSU Boonshoft School of Medicine.
×
About Khalid M. Elased
My current research interests focus on:
1. Understanding and manipulating the Renin-Angiotensin System (RAS) relevant to hypertension and diabetes.
2. Use of MALDI- TOF-MS and SELDI-TOF-MS to develop and optimize miniaturized novel assays for quantitative evaluation of localized and circulating RAS.
3. Our recent work focused on the development of urinary Angiotensin Converting Enzyme (ACE2 ) and neprilysin (NEP) as biomarkers for early detection of Chronic Kidney Disease in diabetic patients.
Our laboratory uses radio telemetry, confocal microscopy, western blot and enzyme assay to investigate the effect of hyperglycemia on blood pressure, renal RAS and progression of CKD in murine model of diabetes and hypertension.
Previous research interests were focused on extraction, purification and characterization of insulin mimetic molecules from Plasmodium yoelii. These molecules are related to Glycosylphosphatiylinositos (GPIs) which could have a potential as new antidiabetic agents.
Research is funded by NHLBI, American Heart Association, WSU Boonshoft School of Medicine.
| Present | Professor, Wright State University ‐ Pharmacology & Toxicology | |
|
|
||
Disciplines
Research Interests
Professional Service and Affiliations
| 2014 - Present | Member, American Society of Physiology (ASP) | 2013 - Present | Member, American Society of Nephrology (ASN) | 2011 - Present | Member, American College of Clinical Pharmacy (ACCP) | 2010 - Present | Member, Delegate of Boonshoft School of Medicine to the United States Pharmacopeia (USP) Conventions | 2004 - Present | Member, American Heart Association (AHA) Council of High Blood Pressure | 1999 - Present | Member, American Diabetic Association (ADA) | 1990 - Present | Member, European Association for the Study of Diabetes (EASD) | 2005 - 2009 | Member, American Society for Pharmacology and Experimental Therapeutics (ASPET) |
| MS, University of Bradford ‐ School of Pharmacy | ||
|
|
||
| B. Pharm, University of Khartoum ‐ School of Pharmacy | ||
|
|
||
| Ph.D., University of Strathclyde | ||
|
|
||
| Pharm.D., Ohio Northern University ‐ School of Pharmacy | ||
|
|
||
Contact Information
Health Sciences Bldg 238
3640 Colonel Glenn Hwy
Dayton, OH 45435-0001
(937) 775-2159
Email: